Neurosciences

Overview

The Neuroscience area is consolidating its position as one of the largest clusters of research labs working on neurological diseases across Europe. Thirteen groups are currently part of this area, working closely with top clinicians at the hospital. The area encompasses different aspects related to neuroscience, such as neural development, neurodegeneration, neuroimmunology, neurological pain, mental health, neurosurgery, pediatric neurology or neuroimaging

There are groups also focused on cell signaling and apoptosis and translational bioinformatics.

Publications

242

total

1850.832

impact factor

7.648

average impact factor

Group Leader: Josep Gámez

team

zoom

download

In 2019, our group has focused its efforts on two areas: 1) the search for genetic susceptibility factors and phenotype modifiers in familial and sporadic forms of autoimmune myasthenia gravis using mass next-generation sequencing techniques, and 2) on the viability of gene therapy TTR-related familial amyloidosis. The latter is an example of our commitment to Translational Medicine (bench-to-bedside).

6

total

126^.302

impact factor

21^.050

average impact factor

SELECTED ARTICLES

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
N Engl J Med. 2018 Jul 5;379(1):22-31.
doi: 10.1056/NEJMoa1716793. PMID: 29972757
IF: 79.258
Vidal-Taboada JM, Pugliese M, Salvadó M, Gámez J, Mahy N, Rodríguez MJ.
KATP Channel Expression and Genetic Polymorphisms Associated with Progression and Survival in Amyotrophic Lateral Sclerosis.
Mol Neurobiol. 2018 Oct;55(10):7962-7972.
doi: 10.1007/s12035-018-0970-7.
IF: 5.076
van Schaik IN, Mielke O; PATH study group.
Intravenous versus subcutaneous immunoglobulin
Lancet Neurol. 2018 May;17(5):393-394.
doi: 10.1016/S1474-4422(18)30109-1.
IF: 27.138
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Neurol. 2018 Jan;17(1):35-46.
doi: 10.1016/S1474-4422(17)30378-2
IF: 27.138
Borrego-Ecija S, Cortes-Vicente E, Cervera-Carles L, Clarimon J, Gamez J, Batlle J, Ricken G, Molina-Porcel L, Aldecoa I, Sanchez-Valle R, Rojas-Garcia R, Gelpi E
Does ALS-FUS without FUS mutation represent ALS-FET? Report of three cases.
Neuropathol Appl Neurobiol. 2018 Oct 29.
doi: 10.1111/nan.12527.
IF: 6,059

View all publications

Neurosciences

Overview

Publications

Group Leader: Josep Gámez

Research Areas